A note on the design of cancer screening trials

Journal of Medical Screening

Volumn 22, Issue 2, 2015, Pages 65-68

  Duffy, Stephen W ^a   Smith, Robert A ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

Cancer screening; follow up; trial design

Indexed keywords

BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMAN; MASS SCREENING;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING;

EID: 84942158165     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1177/0969141315577847     Document Type: Article

References (14)

1. S.Moss. Design issues in cancer screening trials. Stat Methods Med Res2010; 19: 451–61.
2. R.A.SmithS.W.DuffyR.GabeL.TabarA.M.F.Yen. Chen HHT. The randomized trials of breast cancer screening: what have we learned?Radiol Clin N Amer2004; 42: 793–806.
3. P.SasieniJ.AdamsJ.Cuzick. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer2003; 89: 88–93.
4. W.S.AtkinR.EdwardsI.Kralj-HansK.WooldrageA.R.HartJ.M.NorthoverD.M.ParkinJ.WardleS.W.DuffyJ.Cuzick. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet2010; 375: 1624–33.
5. S.NjorL.NyströmS.MossE.PaciM.BroedersN.SegnanE.Lynge. Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen2012; 19(1): Suppl: 33–41.
6. S.W.DuffyO.AgbajeL.TabarB.VitakN.BjurstamL.BjörneldJ.P.MylesJ.Warwick. Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Research2005; 7: 258–65.
7. J.D.HardcastleJ.O.ChamberlainM.H.RobinsonS.M.MossS.S.AmarT.W.BalfourP.D.James. Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet1996; 348: 1472–7.
8. L.TabarC.J.FagerbergA.Gad. Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet1985; i: 829–32.
9. J.H.ScholefiledS.M.MossC.M.ManghamD.K.WhynesJ.D.Hardcastle. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut2012; 61: 1036–40.
10. S.Shapiro. Periodic screening for breast cancer: the HIP radnomized controlled trial. Monogr Natl Cancer Inst1997; 22: 27–30.
11. L.TabarB.VitakT.H.H.ChenA.M.F.YenA.CohenT.TotS.Y.H.ChiuS.L.S.ChenJ.C.Y.FannJ.RosellH.FohlinR.A.SmithS.W.Duffy. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during three decades. Radiol2011; 260: 658–63.
12. L.NyströmI.AnderssonN.BjurstamJ.FrisellB.NordenskjöldL.E.Rutqvist. Long term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet2002; 359: 909–19.
13. S.W.DuffyS.W.DuffyA.YenT.ChenS.ChenS.ChiuJ.FanR.A.SmithB.VitakL.Tabar. Long term benefits of breast screening. Breast Cancer Management2012; 1(1): 31–38.
14. P.C.Gøtzsche. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull2011; 58: A426–A426.